Cogent Biosciences (COGT) FCF Margin (2017 - 2020)
Cogent Biosciences (COGT) posted quarterly FCF Margin of 3290.71% for Q3 2020, down 229218.0% year-over-year from N/an in Q4 2019, and down 108.73% quarter-over-quarter from 1576.52% in Q2 2020.
Cogent Biosciences (COGT) FCF Margin (2017 - 2020) Analysis & Trends
Cogent Biosciences (COGT) has reported FCF Margin for 4 consecutive years, with 3290.71% the latest figure, recorded in Q3 2020.
- In Q3 2020, FCF Margin fell 229218.0% year-over-year to 3290.71%; the TTM figure through Dec 2020 stood at 455.47% (down 27081.0% YoY), while the FY2020 annual figure was 455.47%, down 27081.0% from the prior year.
- FCF Margin retreated to 3290.71% in Q3 2020 per COGT's latest filing, from 1576.52% in the prior quarter.
- Across five years, FCF Margin topped out at 55.32% in Q4 2019 and bottomed at 3290.71% in Q3 2020.
- Historically, FCF Margin has averaged 633.78% across 4 years, with a median of 362.88% in 2018.
- On a YoY basis, FCF Margin climbed as much as 26638 bps in 2020 and fell as far as 229218 bps in 2020.
- Cogent Biosciences' FCF Margin stood at 309.75% in 2017, then advanced by 23 bps to 237.06% in 2018, then surged by 77 bps to 55.32% in 2019, then plunged by 5848 bps to 3290.71% in 2020.
- Business Quant data shows COGT's FCF Margin at 3290.71% in Q3 2020, 1576.52% in Q2 2020, and 112.26% in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -3,290.71% |
| Jun 30, 2020 | -1,576.52% |
| Mar 31, 2020 | -112.26% |
| Dec 31, 2019 | -55.32% |
| Sep 30, 2019 | -998.53% |
| Jun 30, 2019 | -361.50% |
| Mar 31, 2019 | -378.64% |
| Dec 31, 2018 | -237.06% |
| Sep 30, 2018 | -374.99% |
| Jun 30, 2018 | -498.26% |
| Mar 31, 2018 | -362.88% |
| Dec 31, 2017 | -309.75% |
| Sep 30, 2017 | -247.45% |
| Jun 30, 2017 | -287.54% |
| Mar 31, 2017 | -415.33% |